Developer docs
API playgroundTry for free, no card

Search company profiles

DermTech

Full company profile

uuid0003yo1

Namestring
DermTech
Legal namestring
DermTech, LLC
Websiteurl
dermtech.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

DermTech 2.0 (operating as DermTech, LLC) is a US-based skin genomics platform company headquartered in San Diego, California, with a CLIA-certified, Joint Commission-accredited laboratory. The company develops and commercializes the DermTech Melanoma Test (Pigmented Lesion Assay®), a physician-ordered laboratory-developed test that uses proprietary Smart Sticker® adhesive patches to painlessly collect skin cells from pigmented lesions for RNA gene expression analysis of LINC00518 and PRAME markers, delivering a reported 99% negative predictive value to support dermatologists' biopsy decisions. DermTech serves dermatology practices and their patients across the United States, with Medicare LCD #38151 coverage providing $0 out-of-pocket costs for eligible beneficiaries and additional billing through Tricare and commercial insurers. A second line of business, DermTech Stratum, provides precision biomarker services — including clinical trial support, genomic analysis, and tissue banking — to biopharmaceutical and research partners.

Revenue is generated primarily through per-test insurance billing under a one-time laboratory testing model, supplemented by professional services revenue from Stratum biopharma engagements. The go-to-market is an enterprise field sales motion into dermatology practices, supported by a physician portal, customer service onboarding, and inclusion in the NCCN Clinical Practice Guidelines for Melanoma: Cutaneous. Following an August 2024 asset sale, the company operates under new ownership (James E. Stowers III, Chairman; Burkhard Jansen, M.D., President), with leadership focused on rebuilding the diagnostic franchise and expanding the Stratum services platform for biopharma drug discovery in cancers and inflammatory diseases.

Short descriptiontext

DermTech 2.0 is a US-based skin genomics platform that commercializes the DermTech Melanoma Test, a non-invasive Smart Sticker-based qPCR assay measuring LINC00518 and PRAME to help dermatologists rule out melanoma, and offers DermTech Stratum biomarker services to biopharma and research partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-invasive skin genomics, melanoma diagnostic testing, RNA gene expression assays, precision biomarker services, adhesive skin biopsy
Industry3 codes
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAKACAC
Dermatopathology
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Cancer Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Laboratory Testing Services
TypeOne Time License
Description

The DermTech Melanoma Test is a physician-ordered laboratory-developed test. Revenue generated through insurance billing to Medicare, Tricare, and commercial insurers. Patients may have $0 out-of-pocket costs for Medicare-covered tests.

dermtech.com
2Clinical Trial Support Services (DermTech Stratum)
TypeProfessional Services
Description

Services for biopharma and research partners including complete trial management, site access, and genomic analysis of skin samples collected via Smart Stickers. Revenue from pharmaceutical research partnerships and tissue bank services.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Medicare patients - $0 out-of-pocket
ModelOtherBilling cadencePay-as-you-go
Notes

The DermTech Melanoma Test is covered by Medicare with $0 out-of-pocket costs for eligible patients. Coverage criteria specified under LCD #38151.

dermtech.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1DermTech Melanoma Test
Description

Non-invasive genomic test for melanoma detection using Smart Sticker technology with 99% NPV.

dermtech.com
+3 more records
Core offering1 text field

DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker adhesive patches. Its primary commercial offering is the DermTech Melanoma Test (Pigmented Lesion Assay), a physician-ordered laboratory-developed test that analyzes LINC00518 and PRAME gene expression markers to aid dermatologists in biopsy decisions for pigmented lesions. The company also operates DermTech Stratum, a precision biomarker services platform offering clinical trial support, genomic analysis of skin samples, and tissue banking for biopharmaceutical and research partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99% negative predictive value (NPV) for melanoma rule-out
+3 more records
Product overview1 text field

DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Stickers. The core offering is the DermTech Melanoma Test (also known as the Pigmented Lesion Assay), which detects genomic markers associated with melanoma to aid dermatologists in biopsy decisions. The company also offers DermTech Stratum, a separate platform providing precision biomarker services for biopharmaceutical and research partners, including clinical trial support services. The Smart Stickers serve as the foundational collection technology that enables both the diagnostic test and research services.

Product and service2 records
1DermTech Melanoma Test (Pigmented Lesion Assay)
CategoryDiagnostic Laboratory Test
Description

Physician-ordered laboratory-developed test that analyzes RNA expression of LINC00518 and PRAME markers in skin cells collected non-invasively via Smart Sticker to rule out melanoma in pigmented lesions meeting ABCDE criteria. Performed at the company's CLIA-certified laboratory with results returned in approximately 5 business days.

2DermTech Stratum
CategoryBiomarker Research Services
Description

Precision biomarker services platform for biopharmaceutical and research partners offering non-invasive skin genomics services, clinical trial support including complete trial management and site access, genomic analysis of skin samples collected via Smart Stickers, and curated tissue bank access for drug discovery in cancers and inflammatory diseases.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Biopharma and research partners (unspecified)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

DermTech Stratum platform expanded to include clinical trial support services targeting biopharma and research partners. Services include complete trial management, site access, and genomic analysis of skin samples collected via Smart Stickers. The company emphasizes its curated tissue bank and platform suitability for drug discovery related to cancers and inflammatory diseases.

prnewswire.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Castle Biosciences markets DecisionDx-Melanoma, a molecular prognostic test for cutaneous melanoma — the most direct head-to-head competitor to the DermTech Melanoma Test in dermatology practices.

TypeDirect peer
Description

Veracyte is a molecular diagnostics company offering gene-expression-based tests in oncology, with a similar physician-channel, evidence-driven commercial model to DermTech.

TypeBroad incumbent
Description

Myriad is an established molecular diagnostics company operating across oncology (including dermatology-adjacent indications), sharing the same specialty-lab, insurance-reimbursed commercial model as DermTech.

TypeBroad incumbent
Description

NeoGenomics provides oncology-focused molecular and genetic testing services with a CLIA lab network, broadly comparable in scale and payor-driven reimbursement model to DermTech.

TypeEmerging player
Description

Skin Analytics uses AI-based image analysis for melanoma triage in dermatology and primary care, representing a non-invasive alternative route to the same melanoma rule-out use case DermTech targets.

TypeEmerging player
Description

Strata inherited the MelaFind non-invasive melanoma detection platform; while a different technology (optical/spectroscopic), it targets the same dermatology melanoma triage use case.

TypeBroad incumbent
Description

Quest is one of the largest US clinical reference laboratories with a dermatopathology and molecular diagnostics franchise that overlaps with DermTech's lab services.

TypeBroad incumbent
Description

Labcorp operates a national clinical and specialty lab network with dermatopathology and oncology molecular services, serving the same physician customer base as DermTech.

TypeDirect peer
Description

Interpace is a specialty molecular diagnostics company offering physician-ordered, insurance-reimbursed lab tests in oncology — sharing the LDT commercial model DermTech uses.

TypeEmerging player
Description

Dermasensor is developing a non-invasive spectroscopy-based device for skin cancer triage in primary care, addressing an overlapping melanoma rule-out use case.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DermTech

Molecular Cancer Diagnosticsdermtech.com

DermTech 2.0 is a US-based skin genomics platform that commercializes the DermTech Melanoma Test, a non-invasive Smart Sticker-based qPCR assay measuring LINC00518 and PRAME to help dermatologists rule out melanoma, and offers DermTech Stratum biomarker services to biopharma and research partners.

What DermTech does

DermTech 2.0 (operating as DermTech, LLC) is a US-based skin genomics platform company headquartered in San Diego, California, with a CLIA-certified, Joint Commission-accredited laboratory. The company develops and commercializes the DermTech Melanoma Test (Pigmented Lesion Assay®), a physician-ordered laboratory-developed test that uses proprietary Smart Sticker® adhesive patches to painlessly collect skin cells from pigmented lesions for RNA gene expression analysis of LINC00518 and PRAME markers, delivering a reported 99% negative predictive value to support dermatologists' biopsy decisions. DermTech serves dermatology practices and their patients across the United States, with Medicare LCD #38151 coverage providing $0 out-of-pocket costs for eligible beneficiaries and additional billing through Tricare and commercial insurers. A second line of business, DermTech Stratum, provides precision biomarker services — including clinical trial support, genomic analysis, and tissue banking — to biopharmaceutical and research partners.

Revenue is generated primarily through per-test insurance billing under a one-time laboratory testing model, supplemented by professional services revenue from Stratum biopharma engagements. The go-to-market is an enterprise field sales motion into dermatology practices, supported by a physician portal, customer service onboarding, and inclusion in the NCCN Clinical Practice Guidelines for Melanoma: Cutaneous. Following an August 2024 asset sale, the company operates under new ownership (James E. Stowers III, Chairman; Burkhard Jansen, M.D., President), with leadership focused on rebuilding the diagnostic franchise and expanding the Stratum services platform for biopharma drug discovery in cancers and inflammatory diseases.

DermTech firmographics

Firmographics
Name
DermTech
Legal name
DermTech, LLC
Website
https://dermtech.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
51–100 employees
Short description
DermTech 2.0 is a US-based skin genomics platform that commercializes the DermTech Melanoma Test, a non-invasive Smart Sticker-based qPCR assay measuring LINC00518 and PRAME to help dermatologists rule out melanoma, and offers DermTech Stratum biomarker services to biopharma and research partners.
Ownership category
akta.pro rank

DermTech industry classification

Industry
Product category
Molecular Cancer Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAKACAC
Dermatopathology

Keywords

  • Non-invasive skin genomics
  • Melanoma diagnostic testing
  • RNA gene expression assays
  • Precision biomarker services
  • Adhesive skin biopsy

Where DermTech is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

DermTech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Testing Services: The DermTech Melanoma Test is a physician-ordered laboratory-developed test. Revenue generated through insurance billing to Medicare, Tricare, and commercial insurers. Patients may have $0 out-of-pocket costs for Medicare-covered tests.
  2. Clinical Trial Support Services (DermTech Stratum): Services for biopharma and research partners including complete trial management, site access, and genomic analysis of skin samples collected via Smart Stickers. Revenue from pharmaceutical research partnerships and tissue bank services.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedicare patients - $0 out-of-pocket

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

DermTech product offering

Product offering

Core offering

DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker adhesive patches. Its primary commercial offering is the DermTech Melanoma Test (Pigmented Lesion Assay), a physician-ordered laboratory-developed test that analyzes LINC00518 and PRAME gene expression markers to aid dermatologists in biopsy decisions for pigmented lesions. The company also operates DermTech Stratum, a precision biomarker services platform offering clinical trial support, genomic analysis of skin samples, and tissue banking for biopharmaceutical and research partners.

Product overview

DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Stickers. The core offering is the DermTech Melanoma Test (also known as the Pigmented Lesion Assay), which detects genomic markers associated with melanoma to aid dermatologists in biopsy decisions. The company also offers DermTech Stratum, a separate platform providing precision biomarker services for biopharmaceutical and research partners, including clinical trial support services. The Smart Stickers serve as the foundational collection technology that enables both the diagnostic test and research services.

Differentiator

Problem solved

Functional benefit

Brands

  • DermTech Melanoma Test: Non-invasive genomic test for melanoma detection using Smart Sticker technology with 99% NPV.
  • DermTech Stratum
  • Smart Sticker
  • Pigmented Lesion Assay

Products and services

  • DermTech Melanoma Test (Pigmented Lesion Assay) Physician-ordered laboratory-developed test that analyzes RNA expression of LINC00518 and PRAME markers in skin cells collected non-invasively via Smart Sticker to rule out melanoma in pigmented lesions meeting ABCDE criteria. Performed at the company's CLIA-certified laboratory with results returned in approximately 5 business days.
  • DermTech Stratum Precision biomarker services platform for biopharmaceutical and research partners offering non-invasive skin genomics services, clinical trial support including complete trial management and site access, genomic analysis of skin samples collected via Smart Stickers, and curated tissue bank access for drug discovery in cancers and inflammatory diseases.

Quantifiable outcome

  • 99% negative predictive value (NPV) for melanoma rule-out
  • +3 more outcomes

Companies that use DermTech

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

DermTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

DermTech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biopharma and research partners (unspecified)coreStrategic or Co-development Partner · 26 March 2026DermTech Stratum platform expanded to include clinical trial support services targeting biopharma and research partners. Services include complete trial management, site access, and genomic analysis of skin samples collected via Smart Stickers. The company emphasizes its curated tissue bank and platform suitability for drug discovery related to cancers and inflammatory diseases.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

DermTech competitors and assessment

Company assessment

Direct peers

  • Castle Biosciences: Castle Biosciences markets DecisionDx-Melanoma, a molecular prognostic test for cutaneous melanoma — the most direct head-to-head competitor to the DermTech Melanoma Test in dermatology practices.
  • Veracyte: Veracyte is a molecular diagnostics company offering gene-expression-based tests in oncology, with a similar physician-channel, evidence-driven commercial model to DermTech.
  • Interpace Biosciences: Interpace is a specialty molecular diagnostics company offering physician-ordered, insurance-reimbursed lab tests in oncology — sharing the LDT commercial model DermTech uses.

Broad incumbents

  • Myriad Genetics: Myriad is an established molecular diagnostics company operating across oncology (including dermatology-adjacent indications), sharing the same specialty-lab, insurance-reimbursed commercial model as DermTech.
  • NeoGenomics: NeoGenomics provides oncology-focused molecular and genetic testing services with a CLIA lab network, broadly comparable in scale and payor-driven reimbursement model to DermTech.
  • Quest Diagnostics: Quest is one of the largest US clinical reference laboratories with a dermatopathology and molecular diagnostics franchise that overlaps with DermTech's lab services.
  • Labcorp: Labcorp operates a national clinical and specialty lab network with dermatopathology and oncology molecular services, serving the same physician customer base as DermTech.

Emerging players

  • Skin Analytics: Skin Analytics uses AI-based image analysis for melanoma triage in dermatology and primary care, representing a non-invasive alternative route to the same melanoma rule-out use case DermTech targets.
  • Strata Skin Sciences (MelaFind legacy): Strata inherited the MelaFind non-invasive melanoma detection platform; while a different technology (optical/spectroscopic), it targets the same dermatology melanoma triage use case.
  • Dermasensor: Dermasensor is developing a non-invasive spectroscopy-based device for skin cancer triage in primary care, addressing an overlapping melanoma rule-out use case.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

DermTech social profiles

Digital presence

DermTech compliance and trust

Trust signal

Compliance3 records

DermTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DermTech leadership team

Management profile

Number of profiles

Profiles6 records

DermTech funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DermTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DermTech

What does DermTech do?

DermTech 2.0 is a platform technology company that provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker adhesive patches. Its primary commercial offering is the DermTech Melanoma Test (Pigmented Lesion Assay), a physician-ordered laboratory-developed test that analyzes LINC00518 and PRAME gene expression markers to aid dermatologists in biopsy decisions for pigmented lesions. The company also operates DermTech Stratum, a precision biomarker services platform offering clinical trial support, genomic analysis of skin samples, and tissue banking for biopharmaceutical and research partners.

Is DermTech a public or private company?

DermTech is a private company. It is classified as unknown and is currently operating.

When was DermTech founded?

DermTech was founded in 2024. It employs 51 to 100 people.

Where is DermTech based?

DermTech is headquartered in San Diego, United States, in the North America region.

How does DermTech make money?

Two revenue lines are on record. Laboratory Testing Services are the primary driver. The others are clinical Trial Support Services (DermTech Stratum).

Who are DermTech's main competitors?

Direct peers on record are Castle Biosciences, Veracyte and Interpace Biosciences. Broad incumbents are Myriad Genetics, NeoGenomics, Quest Diagnostics and Labcorp. Emerging players are Skin Analytics, Strata Skin Sciences (MelaFind legacy) and Dermasensor.

Does DermTech have an API?

No public API is recorded for DermTech.

What industry is DermTech in?

DermTech's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GoldrushcamDermTech to Pay Up to $5 Million to Resolve Allegations It Submitted False Claims to Medicare for Unreliable Skin Cancer TestsDermTech Inc. agreed to settle allegations of submitting false Medicare claims for unreliable skin cancer tests, paying up to $5,038,011. The settlement covers billing for tests with unvalidated controls and insufficient patient RNA, and a former employee will receive 20% of the recovery.EIN PresswireBringing Dermatology to the Frontline: Opportunities for DermTech in Primary Care SettingsA study published in SKIN: The Journal of Cutaneous Medicine reviews the Pigmented Lesion Assay, a painless skin patch test that analyzes two genes to rule out melanoma with over 99% accuracy. The test reduced unnecessary biopsies from 20-25 to about three per melanoma in dermatology offices, and works across all skin tones. Researchers call for larger primary care studies and consistent insurance coverage.PR NewswireDermTech 2.0 Further Expands DermTech Stratum with Clinical Trial Support ServicesDermTech 2.0 (DermTech LLC) announced the further expansion of its precision biomarker service platform, DermTech Stratum, to include complete clinical trial and protocol support services such as site access and dedicated clinical trial management support. The expanded offering leverages the company's non-invasive Smart Sticker skin sample collection technology and its curated clinical tissue bank containing over 10,000 non-invasively obtained skin samples from various skin conditions. The services are being used to support drug discovery and development focused on cancers and inflammatory diseases in clinical research studies, with over 30 pharma and research partners currently utilizing DermTech Stratum services.openPR.comSkin Cancer Diagnostics Market Outlook 2026-2033: Growth Drivers, Trends, and Strategic Insights • DermTech • NeoGenomicsThe article reports on the publication of a market outlook study for the Skin Cancer Diagnostics market by Worldwide Market Reports, covering the forecast period from 2026 to 2033. The report analyzes major players, regional performance, market segments, and technological trends, highlighting growth opportunities and strategic insights.BenzingaCrude Oil Rises 1%; DermTech Shares PlummetDermTech, Inc. shares plummeted 58% after the company filed for Chapter 11 bankruptcy protection and reduced its workforce by 20% to preserve cash. In other market movements, Reliance Global Group surged 258% on expectations of closing its acquisition of Spetner Associates, while Taysha Gene Therapies dropped 31% following the release of clinical trial data.San Diego Union-TribuneMaker of melanoma skin patch files for Chapter 11 bankruptcyDermTech, a San Diego-based skin cancer detection company, filed for Chapter 11 bankruptcy protection on Tuesday to restructure debt and sell assets. The company plans to lay off 15 employees (20% of its workforce) and faces a cash crunch, with total assets of about $98 million and debts of $63 million.BovnewsIn the current cycle, DermTech Inc (DMTK) Stock is showing signs of growth – BOVNewsAnalysts have raised price targets for DermTech Inc, with Oppenheimer, BTIG, Stephens, and Cowen all rating the stock positively. The company beat its Q4 EPS estimate by $0.04, but its stock has fallen 73.29% over six months. Insider sales by the CFO and COO were disclosed in December 2023.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DermTech, Inc. - DMTKPomerantz LLP announced on November 28, 2023 that it is investigating claims on behalf of investors of DermTech, Inc. (NASDAQ: DMTK) over possible securities fraud or unlawful business practices by the company and certain officers or directors. The investigation follows two stock drops: 34% to $5.56 on August 9, 2022, and 44.7% to $1.66 on November 4, 2022, after the company lowered its 2022 assay revenue guidance to at least $13 million.PR NewswireDMTK Investors Have Opportunity to Lead DermTech, Inc. Securities Fraud LawsuitThe Law Offices of Howard G. Smith announced a securities fraud class action lawsuit against DermTech, Inc. (NASDAQ: DMTK), with a class period from May 3, 2022 to November 3, 2022 and a lead plaintiff deadline of December 15, 2023. The complaint alleges that defendants failed to disclose challenges with collections from commercial payors, resulting in lower average selling prices for DermTech's DMT product and adverse impacts to revenue growth. Investors who suffered substantial losses are being invited to lead the class action or contact the firm to discuss their legal rights.PR NewswireSHAREHOLDER ALERT: Levi & Korsinsky Notifies DermTech, Inc.(DMTK) Investors of a Class Action Lawsuit and Upcoming DeadlineLevi & Korsinsky, LLP has filed a class action securities lawsuit against DermTech, Inc. (NASDAQ: DMTK) on behalf of investors who suffered losses due to alleged securities fraud between May 3, 2022 and November 3, 2022. The complaint alleges that defendants made false statements regarding challenges with collections from commercial payors, which resulted in a lower average selling price for the DermTech Melanoma Test and adversely impacted revenue growth. Investors who suffered losses have until December 15, 2023 to request appointment as lead plaintiff in the case.